First clinical experience on the ACURATE TF™ Transfemoral Aortic Bioprosthesis Implantation in Patients with Severe Aortic Stenosis to collect human data pertaining to the safety and performance of the device from three different cohorts
A prospective, multicenter, "CE-approval cohort" analysis with the Symetis ACURATE TF™ Transfemoral Aortic Bioprosthesis for minimal invasive implantation via transfemoral access to treat patients with severe aortic stenosis where conventional aortic valve replacement (AVR) via open heart surgery is considered to be associated with high risk, to evaluate the feasibility and performance of the implantation at 30-Days and at 1-Year Follow-up.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
89
ACURATE TF™Transfemoral Aortic Bioprosthesis is intended for subjects with severe symptomatic Aortic Stenosis and are considered high risk for surgical conventional Aortic Valve Replacement .
Instituto Dante Pazzanese de Cardiologia
São Paulo, Brazil
Kerckhoff Klinik GmbH
Bad Nauheim, Germany
Universitätsklinikum Bonn
Bonn, Germany
Herzzentrum Universitätsklinikum Köln
Cologne, Germany
Freedom from all-cause mortality
Rate of all-cause mortality
Time frame: 30-Day Follow-up
Rate of MACCE (major cardiac and cerebrovascular event) related to the ACURATE TF™ Transfemoral Aortic Bioprosthesis and Delivery System.
Rate of major cardiac and cerebrovascular event (MACCE) at 30 days and at 12 months follow-up related to ACURATE TF™ Transfemoral Aortic Bioprosthesis and Delivery System and defined as all cause death, myocardial infarction, re-intervention and stroke.
Time frame: 30-Days and 12 Months Follow-up
Change in NYHA class over time
Functional improvement from baseline NYHA classification at 30 day and at 12 month follow-up.
Time frame: 30-Day and 12-Month
Procedural success during device implantation
Procedural Success defined as stable study device placement at intended site and adequate device functioning immediately post-implantation, confirmed by angiography and echocardiography and without intra-procedural mortality.
Time frame: intraoperative
Device success
Device success is defined as adequate functioning of the study device as confirmed by angiography and/or echocardiography. The following data points will be analyzed for adequate functioning of the study device: * Effective orifice area and index (EOA) * Peak jet velocity * Transvalvular aortic gradient (mean) * Paravalvular and intravalvular (central) leak * Aortic Insufficiency * Valve function and morphology
Time frame: 30-Day and 12-Month Follow-up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Universitäres Herzzentrum Hamburg
Hamburg, Germany
Osaka University Hospital
Osaka, Japan